Finith E. Jernigan, Ph.D.
Affiliations: | 2013 | Chemistry | University of North Carolina, Chapel Hill, Chapel Hill, NC |
| 2013-2016 | Harvard Medical School, Boston, MA, United States | ||
| 2016-2018 | Silicon Therapeutics | ||
| 2019-2020 | PTC Therapeutics, Inc. | ||
| 2020- | Roivant Sciences |
Area:
Chemical Biology, Computational Drug DiscoveryGoogle:
"Finith Jernigan"Mean distance: 8.83
Parents
Sign in to add mentor| David S. Lawrence | grad student | 2013 | UNC Chapel Hill | |
| (Synthesis and development of proteasome and kinase fluorescent assays for quantitation of enzyme activity.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ghalali A, Rice JM, Kusztos A, et al. (2019) Developing a novel FRET assay, targeting the binding between Antizyme-AZIN. Scientific Reports. 9: 4632 |
| Priestman MA, Wang Q, Jernigan FE, et al. (2015) Multicolor monitoring of the proteasome's catalytic signature. Acs Chemical Biology. 10: 433-40 |
| Oien NP, Nguyen LT, Jernigan FE, et al. (2014) Long-wavelength fluorescent reporters for monitoring protein kinase activity. Angewandte Chemie (International Ed. in English). 53: 3975-8 |
| Jernigan FE, Lawrence DS. (2013) A broad spectrum dark quencher: construction of multiple colour protease and photolytic sensors. Chemical Communications (Cambridge, England). 49: 6728-30 |
| Agnes RS, Jernigan F, Shell JR, et al. (2010) Suborganelle sensing of mitochondrial cAMP-dependent protein kinase activity. Journal of the American Chemical Society. 132: 6075-80 |